{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T01:29:22Z","timestamp":1761182962530,"version":"build-2065373602"},"reference-count":14,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jiac-j.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2012]]},"DOI":"10.1007\/s10156-012-0397-4","type":"journal-article","created":{"date-parts":[[2012,3,7]],"date-time":"2012-03-07T01:22:55Z","timestamp":1331083375000},"page":"241-246","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"title":["The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection"],"prefix":"10.1016","volume":"18","author":[{"given":"Yoshihiro","family":"Yamamoto","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koichi","family":"Izumikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeki","family":"Nakamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshifumi","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taiga","family":"Miyazaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kakeya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shigeru","family":"Kohno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Hashiguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Fukuda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsutomu","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akira","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichi","family":"Inoue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitomo","family":"Morinaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Yanagihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1007\/s10156-012-0397-4_bib0005","first-page":"762","article-title":"Report: Clinical evaluation methods for new antimicrobial agents for the treatment of respiratory tract infections","volume":"45","author":"Saito","year":"1997","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0010","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1093\/jac\/dkm258","article-title":"Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S. aureus (MRSA) blood isolates from 2001\u201305","volume":"60","author":"Steinkraus","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0015","unstructured":"Japan Nosocomial Infection Surveillance (Internet) Japan; (cited 01 Nov 2011). Available from: http:\/\/www.nih-janis.jp\/report\/open_report\/2010\/3\/2\/zen_Open_Report_201000.pdf"},{"key":"10.1007\/s10156-012-0397-4_bib0020","first-page":"494","article-title":"Epidemiological survey of drug resistance of methicillin-resistant Staphylococcus aureus isolated in Japan in 2000","volume":"50","author":"Kurazono","year":"2002","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1093\/jac\/39.4.471","article-title":"Comparative studies of the bactericidal, morphological and post-antibiotic effects of arbekacin and vancomycin against methicillin-resistant Staphylococcus aureus","volume":"39","author":"Watanabe","year":"1997","journal-title":"J Antimicrob Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0030","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.diagmicrobio.2004.06.014","article-title":"Clinical glycopeptide-intermediate staphylococci tested against arbekacin, daptomycin, and tigecycline","volume":"50","author":"LaPlante","year":"2004","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1007\/s10156-012-0397-4_bib0035","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(03)14959-8","article-title":"Acquisition of 16S rRNA methylase gene in Pseudomonas aeruginosa","volume":"362","author":"Yokoyama","year":"2003","journal-title":"Lancet"},{"key":"10.1007\/s10156-012-0397-4_bib0040","first-page":"91","article-title":"Susceptibility to arbekacin of clinical strains of Pseudomonas aeruginosa isolated in the Tohoku area between 2003 and 2007","volume":"57","author":"Fujimura","year":"2009","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0045","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1128\/AAC.01173-09","article-title":"In vitro activity of the aminoglycoside antibiotic arbekacin against Acinetobacter baumannii-calcoaceticus isolated from war-wounded patients at Walter Reed Army Medical Center","volume":"54","author":"Zapor","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0050","first-page":"299","article-title":"An open clinical study of arbekacin 200mg q.d. in patients infected with methicillin-resistant Staphylococcus aureus (MRSA): a clinical pharmacology study","volume":"56","author":"Aikawa","year":"2008","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0055","first-page":"55","article-title":"Postmarketing surveillance review of arbekacin sulfate in patients with therapeutic drug monitoring","volume":"27","author":"Kawano","year":"2010","journal-title":"Jpn J Ther Drug Monit"},{"key":"10.1007\/s10156-012-0397-4_bib0060","first-page":"469","article-title":"Study of clinical significance of PK\/PD (pharmacokinetic\/pharmacodynamic) parameters after administering arbekacin to patients with pulmonary methicillin-resistant Staphylococcus aureus infection","volume":"52","author":"Tanikaze","year":"2004","journal-title":"Jpn J Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0065","doi-asserted-by":"crossref","first-page":"3763","DOI":"10.1128\/AAC.00480-05","article-title":"Pharmacokinetic\u2013pharmacodynamic relationship of arbekacin for treatment of patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Sato","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1007\/s10156-012-0397-4_bib0070","doi-asserted-by":"crossref","first-page":"3754","DOI":"10.1128\/AAC.00420-05","article-title":"Population pharmacokinetics of arbekacin in patients infected with methicillin-resistant Staphylococcus aureus","volume":"50","author":"Tanigawara","year":"2006","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1270332X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X1270332X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.springerlink.com\/index\/pdf\/10.1007\/s10156-012-0397-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T18:49:51Z","timestamp":1761158991000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X1270332X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012]]},"references-count":14,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2012]]}},"alternative-id":["S1341321X1270332X"],"URL":"https:\/\/doi.org\/10.1007\/s10156-012-0397-4","relation":{},"ISSN":["1341-321X"],"issn-type":[{"type":"print","value":"1341-321X"}],"subject":[],"published":{"date-parts":[[2012]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The efficacy and safety of high-dose arbekacin sulfate therapy (once-daily treatment) in patients with MRSA infection","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1007\/s10156-012-0397-4","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2012 Japanese Society of Chemotherapy and the Japanese Association for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}